Form 4: Haemonetics Corp Executive James D'Arecca Reports Stock Transaction

EVP and Chief Financial Officer of Haemonetics Corp, James D'Arecca, reports disposition of shares to cover tax obligations related to vesting restricted stock units.

Summary

• On May 2, 2025, James D'Arecca, EVP and Chief Financial Officer of Haemonetics Corp, reported a transaction involving common stock.
• 654 shares were disposed of at a price of $63.85 to cover tax obligations related to the vesting of restricted stock units (RSUs).
• Following the transaction, D'Arecca beneficially owns 16,692 shares, including unvested RSUs.

Sentiment

Score: 5

Explanation: This is a neutral report of a routine transaction. It doesn't indicate positive or negative sentiment about the company's performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a standard transaction related to tax obligations on vested equity.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on stakeholders as it is a routine sale of shares for tax purposes.

Key Dates

Keywords

Form 4, Haemonetics Corp, James D'Arecca, Stock Transaction, EVP, Chief Financial Officer, RSUs, HAE